Nivolumab vs Ramipril
Nivolumab vs Ramipril: Overview
This comparison examines the pharmacological differences between Nivolumab and Ramipril.
Mechanism of Action
Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.
Ramipril: Prodrug converted to ramiprilat; ACE inhibitor.
Pharmacokinetics
Half-life: Nivolumab β 27 days; Ramipril β 13-17 hours.
Chemical Properties
Molecular Formula: Ramipril β C23H32N2O5.
Molecular Weight: Ramipril β 416.5120 g/mol.
Type: Nivolumab β Antibody; Ramipril β Small molecule.